Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.46 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20285246 | 0.90 | ALDH1A1 (0.48) | S100A4AGPAT2ALDH1A1LMNAMAPK1 | |
| SCHEMBL13069277 | 0.88 | PTPRC (0.47) | S100A4AGPAT2ALDH1A1LMNAMAPK1 | |
| SCHEMBL14873562 | 0.87 | S100A4 (0.41) | S100A4AGPAT2ALDH1A1MAPK1PTPRC | |
| SCHEMBL15840157 | 0.86 | AGPAT2 (0.37) | S100A4AGPAT2ALDH1A1LMNAMAPK1 | |
| SCHEMBL26347192 | 0.86 | ALOX15 (0.48) | ALDH1A1LMNAMAPK1BCL2MCL1 | |
| SCHEMBL277458 | 0.82 | BIRC5 (0.43) | S100A4AGPAT2ALDH1A1MAPK1PTPRC | |
| SCHEMBL16453890 | 0.82 | BIRC5 (0.43) | S100A4AGPAT2ALDH1A1MAPK1PTPRC | |
| SCHEMBL6326863 | 0.81 | ESR2 (0.48) | ALDH1A1LMNAMAPK1PTPRCCYP2A6 | |
| SCHEMBL22820090 | 0.81 | PTGS2 (0.39) | S100A4AGPAT2ALDH1A1MCL1BIRC5 | |
| SCHEMBL12707406 | 0.81 | TDO2 (0.42) | AGPAT2CYP2A6IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3250035-B1 | COMPOUNDS AND THEIR USE AS BACE1 INHIBITORS | ALLGENESIS BIOTHERAPEUTICS INC (TW) | 2023-01-25 | — | — | EP | disclosed |
| US-11038124-B2 | Organic compound and organic electroluminescence device using the same | LUMINESCENCE TECHNOLOGY CORP. (TW) | 2021-06-15 | — | — | US | disclosed |
| US-20170244049-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-24 | — | — | US | disclosed |
| US-RE45850-E1 | Composition of organic compounds, optical film and method of production thereof | CRYSOPTIX K.K. (JP) | 2016-01-19 | — | — | US | disclosed |
| EP-2638126-B1 | NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER | CRYSOPTIX KK (JP) | 2015-02-18 | — | — | EP | disclosed |
| US-8895118-B2 | Negative dispersion retardation plate and achromatic circular polarizer | CRYSOPTIX K.K. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20140334002-A1 | PATTERNED RETARDER | CRYSOPTIX KK (JP) | 2014-11-13 | — | — | US | disclosed |
| EP-2630523-A1 | RETARDER AND LIQUID CRYSTAL DISPLAY COMPRISING THE SAME | CRYSOPTIX K.K. (JP) | 2013-08-28 | — | — | EP | disclosed |
| US-8512824-B2 | Composition of organic compounds, optical film and method of production thereof | CRYSOPTIX KK (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2622392-A1 | PATTERNED RETARDER | CRYSOPTIX K.K. (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130003178-A1 | THREE-DIMENSIONAL CIRCULAR POLARIZATION EYEGLASSES | CRYSOPTIX KK (JP) | 2013-01-03 | — | — | US | disclosed |
| WO-2013003780-A1 | THREE-DIMENSIONAL CIRCULAR POLARIZATION EYEGLASSES | CRYSOPTIX KK (JP) | 2013-01-03 | — | — | WO | disclosed |
| US-20120113380-A1 | NEGATIVE DISPERSION RETARDATION PLATE AND ACHROMATIC CIRCULAR POLARIZER | CRYSOPTIX KK (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120099052-A1 | RETARDER AND LIQUID CRYSTAL DISPLAY COMPRISING THE SAME | CRYSOPTIX KK (JP) | 2012-04-26 | — | — | US | disclosed |
| WO-2012052950-A1 | RETARDER AND LIQUID CRYSTAL DISPLAY COMPRISING THE SAME | CRYSOPTIX KK (JP) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012044867-A1 | PATTERNED RETARDER | CRYSOPTIX KK (JP) | 2012-04-05 | — | — | WO | disclosed |
| US-20120081784-A1 | PATTERNED RETARDER | CRYSOPTIX KK (JP) | 2012-04-05 | — | — | US | disclosed |
| EP-2331655-A2 | COMPOSITION OF ORGANIC COMPOUNDS, OPTICAL FILM AND METHOD OF PRODUCTION THEREOF | CRYSOPTIX K.K. (JP) | 2011-06-15 | — | — | EP | disclosed |
| US-20100085521-A1 | Composition of Organic Compounds, Optical Film and Method of Production Thereof | CRYSOPTIX KK (JP) | 2010-04-08 | — | — | US | disclosed |
| WO-2010020928-A2 | COMPOSITION OF ORGANIC COMPOUNDS, OPTICAL FILM AND METHOD OF PRODUCTION THEREOF | CRYSOPTIX KK (JP) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11038124-B2 | Organic compound and organic electroluminescence device using the same | TRPA1, TRPC6, TRPM4 | S100A4 3020/4885AGPAT2 2920/4885ALDH1A1 453/4885 |
| US-20170244049-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | CYBA, DDT, DRD1 | S100A4 2174/4885AGPAT2 2894/4885ALDH1A1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.